Back

Finerenone with empagliflozin according to body mass index in chronic kidney disease and type 2 diabetes

30 August 2026 (14:50 - 15:00)
Organised by: Logo
Congress Presentation Part of: Unexpected consequences of cardiometabolic disease Obesity ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

2 More presentations in this session

Presentation thumbnail
SGLT2 inhibitor empagliflozin remodels pericardial fat–derived lipids-initiated ventricular ion‑channel function to reduce arrhythmogenic electrical remodeling in diabetic hearts
Doctor Y. Lin (Kaohsiung, TW)
Abstract Slides
Presentation thumbnail
Dementia in patients with type 2 diabetes: a nationwide Danish study
Ms H. Christensen (DK)
Abstract Slides

Access the full session

Session thumbnail
Unexpected consequences of cardiometabolic disease
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 14:50 CET
You may be interested in
thumbnail
Congress Presentation
Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials
19 May 2025
thumbnail
Congress Presentation
Transition of body mass index status from childhood to adulthood and cardiovascular-kidney-metabolic syndrome in midlife: a 36-year prospective cohort study
1 September 2025
thumbnail
Congress Presentation
Obesity and renal impairment in patients with heart failure and reduced ejection fraction: another obesity paradox?
2 September 2024
thumbnail
Congress Presentation
Impact of BMI on clinical outcomes in all-comers patients with coronary artery disease undergoing PCI: insights from the Global Leaders study
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources